Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
FDA Okays LLY's Omvoh for Second Inflammatory Bowel Disease Condition
08:51am, Thursday, 16'th Jan 2025
FDA approves Lilly's Omvoh for Crohn's disease, expanding its use to the second major type of IBD condition.
My 10 Top Stocks to Buy to Start the New Year Off Right
03:15am, Thursday, 16'th Jan 2025
Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double digits. Investor enthusiasm about technology and growth stocks, and the econo
US FDA approves expanded use of Lilly's bowel disease drug
04:24pm, Wednesday, 15'th Jan 2025
Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's disease, a type of chronic inflammatory bowel disease.
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
04:06pm, Wednesday, 15'th Jan 2025
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year Among those who achieved clinical remiss
Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
03:18pm, Wednesday, 15'th Jan 2025
Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly cuts Q4 sales forecast, but analyst remains bullish on stock—here's why
03:11pm, Wednesday, 15'th Jan 2025
Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 million below the low end of the company's prior guidance and includes $3.5
NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down
02:31pm, Wednesday, 15'th Jan 2025
Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales growth of its tirzepatide products in Q4.
Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall
02:21pm, Wednesday, 15'th Jan 2025
Just before the JP Morgan healthcare conference, Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth
Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip
12:01pm, Wednesday, 15'th Jan 2025
Eli Lilly slashes the revenue guidance for the fourth quarter and fiscal 2024 but offers a bullish outlook for 2025.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
10:01am, Wednesday, 15'th Jan 2025
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
LLY Stock Down on Lower-Than-Expected Sales Guidance for Q4
09:11am, Wednesday, 15'th Jan 2025
LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates.
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?
09:06am, Wednesday, 15'th Jan 2025
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024.
Buy, Sell, Or Hold LLY Stock At $750?
08:25am, Wednesday, 15'th Jan 2025
Eli Lilly stock (NYSE: LLY) fell over 6% on Tuesday, January 14, after it announced that the sales of its obesity drugs are seeing slower than anticipated growth. It has adjusted its Q4 revenue foreca
Has Eli Lilly Stock Peaked?
08:15am, Wednesday, 15'th Jan 2025
Eli Lilly (LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first healthc
Here's why Eli Lilly stock is crashing
07:39am, Wednesday, 15'th Jan 2025
Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 revenue guidance, which fell short of Wall Street expectations.
